NCT00353080View on ClinicalTrials.gov

Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women

PHASE3CompletedINTERVENTIONAL

Enrollment

171

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

risedronate (HMR4003)

Trial Locations (5)

Unknown

Sanofi-Aventis, Helsinki

Sanofi-Aventis, Gouda

Sanofi-Aventis, Oslo

Sanofi-Aventis, Madrid

Sanofi-Aventis, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Procter and Gamble

INDUSTRY

lead

Sanofi

INDUSTRY

NCT00353080 - Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women | Biotech Hunter | Biotech Hunter